Chemotherapy for early-stage breast cancer: the more the better?

[...]these results, based on comparing a range of trials, should be interpreted with caution. [...]the balance of benefit versus toxicity needs to be considered carefully for escalation in chemotherapy. According to the results, concurrent taxane and anthracycline for six cycles seems to be the preferred regimen to achieve optimum survival benefit, with similar proportional reductions irrespective of patient age or tumour characteristics, including size, grade, nodal involvement, hormone receptor status, or HER2 expression.